<!DOCTYPE html>
<html>
<head>
<meta http-equiv="Content-Type" content="text/html; charset=utf-8" />
<meta name="robots" content="noindex">
<meta name="viewport" content="width=device-width, initial-scale=1.0, maximum-scale=1.0">
<link href="css-reset.css" rel="stylesheet" type="text/css">
<link href="style.css" rel="stylesheet" type="text/css">
<link rel="shortcut icon" href="favicon.ico" type="image/x-icon">
<link rel="icon" href="favicon.ico" type="image/x-icon">
<title>IONSYS™ (fentanyl iontophoretic transdermal system)</title> 
</head>

<body>
<div class="phonegapBlack">
	<div>
		<div class="introLogo">
		</div>
		<p>
			IONSYS er indiceret til behandling af akutte moderate til svære postoperative smerter hos voksne patienter.
			<br><br>
			IIONSYS er begrænset udelukkende til hospitalsbrug. Behandling skal indledes og forblive under opsyn af en læge med erfaring i opioidbehandling.
			<br><br>
			Tap to continue.
		</p>
	</div>
</div>
<div class="languageBar">
	<div class="languageList hiddenList">
		<ul>
			<a href="index_AT.html"><li class="language "><span>AT</span></li></a>
			<a href="index_DE.html"><li class="language "><span>DE</span></li></a>
			<a href="index_FI.html"><li class="language "><span>FI</span></li></a>
			<a href="index_FR.html"><li class="language "><span>FR</span></li></a>
			<a href="index.html"><li class="language "><span>GB</span></li></a>
			<a href="index_NL.html"><li class="language "><span>NL</span></li></a>
			<a href="index_NO.html"><li class="language "><span>NO</span></li></a>
			<a href="index_SE.html"><li class="language "><span>SE</span></li></a>
		</ul>
	</div>	
	<div class="languageSelector"></div>
</div>

<header class="pageHeader frontHeader">
	<div id="headerLogoCircle hidden">
	</div>
</header>

<header class="pageHeader frontHeader powerButtonContainer">
	<button id="powerButton">
		<i class="flaticon-standby"></i>
	</button>
	<button id="powerButtonOff">
		<i class="flaticon-standby"></i>
	</button>
</header>	
<section class="splash">
	<div class="splashLimiter">
		<header class="ionsysLogo">
		</header>
		<div class="backgroundAssembly"></div>
		<div class="container packageAssembly">
			<div class="bottomAssy">
				<div class="bottomAssySnapPoint"></div>
			</div>
			<div class="topAssy" draggable="true">
			</div>
		</div>
		<div class="container workingAssembly hidden">
			<div class="device" id="ionsysSplash">
				<div class="led ledGreen hidden">
				</div>
				<div class="led ledRed hidden">
				</div>
				<div class="doseButton">
				</div>
				<div class="seven-segment">
					<div class="digit tens">
						  <div class="a"></div>
						  <div class="b"></div>
						  <div class="c"></div>
						  <div class="d"></div>
						  <div class="e"></div>
						  <div class="f"></div>
						  <div class="g"></div>
					</div>
					<div class="digit ones">
						  <div class="a"></div>
						  <div class="b"></div>
						  <div class="c"></div>
						  <div class="d"></div>
						  <div class="e"></div>
						  <div class="f"></div>
						  <div class="g"></div>
					</div>
				</div>
			</div>
			<div id="medcoLogo" class="hidden">
				<img src="img-medcologo-long-black-clr.png">
			</div>
		</div>
		<div class="container context invisible">
			<div class="contextOverflow">
				<div class="contextContent">
					<header>
						<h2 id="deviceStatus">
							<p class="statusDefault enable"></p>
							<p class="statusReady">Klar-modus</p>
							<p class="statusDose1">Dosering</p>
							<p class="statusDose2">Dosering</p>
							<p class="statusPsc1">Dårlig hudkontakt</p>
							<p class="statusPsc2">Dårlig hudkontakt</p>
							<p class="statusEou">Slutningen af brugsliv</p>
							<p class="statusEol">Systemfejl</p>
							<p class="statusPoweron">Starter op</p>
							<p class="statusPoweroff"><!-- Powering Off --></p>
							<p class="statusPoweredoff"><!-- Powered Off --></p>
							<p class="statusCustom">custom</p>
						</h2>
					</header>
					<article class="caption">
						<h4 id="modeCaption" class="hidden">
							<p class="statusDefault enable"></p>
							<p class="statusReady">Klar til dosering</p>
							<p class="statusDose1">Indgiver dosis...</p>
							<p class="statusDose2">Indgiver dosis...</p>
							<p class="statusPsc1">INGEN dosis leveres</p>
							<p class="statusPsc2">INGEN dosis leveres</p>
							<p class="statusEou">80 doser eller 24 timer</p>
							<p class="statusEol">ALARM-modus</p>
							<p class="statusPoweron"><!-- Powering On --></p>
							<p class="statusPoweroff"><!-- Powering Off --></p>
							<p class="statusPoweredoff"><!-- Powered Off --></p>
							<p class="statusCustom">custom</p>
						</h4>
						<div id="modeDescription">
							<p class="statusDefault enable"></p>
							<p class="statusReady">
								Systemet er tændt og klar til at indgive en dosis. En dosis kan indgives ved at trykke på dosis-knappen oven på systemet to gange med højst 3 sekunders mellemrum. Der leveres ikke fentanyl i dette modus, før start af en dosis. 
								<span class="mockButton mbEOU">
									Hvis systemet når grænsen på 24 timer eller 80 doser, starter det slutningen af dets brugsliv. 
								</span>
								<span class="mockButton mbEOL">
									Hvis systemet fejler en selvtest eller har lavt batteri, vil der lyde en ALARM, og slutningen af systemet brugsliv starter.  
								</span>
							</p>
							<p class="statusDose1">
								Levering af en fentanyl-dosis. Doseringsperiodens varighed er 10 minutter, hvorunder der forsynes 40 mikrogram lægemiddel til patienten. I denne periode er dosis-knappen deaktiveret, LED'en blinker grønt, og displayet angiver, at systemet er i doseringsmodus ved at skifte mellem den "gående" LCD-animering og de aktuelle doser, som indgives. 
								<span class="mockButton mbPSC">
									Hvis systemet fornemmer dårlig hudkontakt, standser det doseringen, går i Standby-modus, og vender derefter tilbage til Klar-modus. 
								</span>
								<span class="mockButton mbEOU">
									Hvis systemet når grænsen på 24 timer eller 80 doser, starter det slutningen af dets brugsliv.
								</span>
								<span class="mockButton mbEOL">
									Hvis systemet fornemmer kompromitteret hud (dvs. et åbent sår), lyder der en ALARM, og det starter slutningen af dets brugsliv. 
								<span>
							</p>
							<p class="statusPsc1">
								Når en dosis startes, MEN systemet ikke kan bekræfte passende kontakt med patientens hud efter 4 minutter, vil det stoppe dosering, gå i Standby-modus og informere patienten. Dette angives ved et hørbart bip og en LED, som blinker rødt.
								<span>
									 Systemet går i Standby-modus i 15 sekunder og dosistælleren øges ikke. Systemet kan derefter indgive dosen igen, når det returnerer til Klar-modus efter 15 sekunder. 
								</span>
							</p>
							<p class="statusEou">
								Efter indgivelse af 80 doser, eller der er gået 24 timer siden aktivering, går systemet i EOL-modus (End-of-Use, slutningen af brugsliv). Systemet indgiver ikke længere doser, LCD'en blinker det samlede antal doser indgivet, og LED'en blinker ikke.
								<span class="mockButton mbEOL">
									Efter 12 timer i slutningen af sit brugsliv, vil systemet automatisk gå i EOL-modus.
								</span>
								<span>
									Systemet slukkes ved at holde dosis-knappen nede i 6 sekunder. 
								</span>
							</p>
							<p class="statusEol">
								En ALARM-tilstand kan forekomme, hvis der fornemmes kompromitteret hud under dosering, et lavt batteri eller efter 12 timer fra EOL. Den aktuelle dosis blinker på systemets LCD og LED'en vedbliver med at blinke rødt, og der lyder et vedvarende bip. Dette angiver, at systemet har nået slutningen af sit brugsliv, EOL (end-of-life). Ingen doser kan indgives. 
								<span>
									Systemet slukkes ved at holde dosis-knappen nede i 6 sekunder.
								</span>
							</p>
							<p class="statusPoweron"></p>
							<p class="statusPoweroff"></p>
							<p class="statusPoweredoff"></p>
							<p class="statusCustom">custom</p>
						</div>
					</article>
				</div>
			</div>
			<div class="contextArrowContainer">
				<div class="flaticon-arrow395 contextArrow contextArrowClosed"></div>
			</div>
		</div>
		<div class="control">
			<label for="doseNumber"  class="extraButtons hidden" >Set Dose #: </label>
			<input type="number" name="doseNumber" id="doseNumber"  class="extraButtons hidden" min="0" max="99" value="0" ></input>
		</div>
	</div>
</section>
<header class="ionsysLogoBanner hiddenLogo">
	<div class="mdcoLogo">
	</div>
</header>
<section class="infoPage">
	<div class="infoPageContent">
		<table class="infoPageTable">
			<td colspan="2">
				IONSYS er indiceret til behandling af akutte moderate til svære postoperative smerter hos voksne patienter.
			</td>
		</table>
		<table class="infoPageTable">
			<td colspan="2">
			IONSYS er begrænset udelukkende til hospitalsbrug. Behandling skal indledes og forblive under opsyn af en læge med erfaring i opioidbehandling.
			</td>
		</table>
		<table class="infoPageTable">
			<tr>
				<th colspan="2">
					<h3>SYSTEMSPECIFIKATIONER</h3>
				</th>
			</tr>
			<tr>
				<td>
					Aktivt indholdsstof 
				</td>
				<td>
					Fentanyl HCl
				</td>
			</tr>
			<tr>
				<td>
					Absorptionsvej:
				</td>
				<td>
					Transdermal (iontoforese) 
				</td>
			</tr>
			<tr>
				<td>
					Aktivering:
				</td>
				<td>
					Patient dobbeltklikker på knappen til dosering efter behov (to gange inden for 3 sekunder) 
				</td>
			</tr>
			<tr>
				<td>
					Dosering: 
				</td>
				<td>
					Forprogrammeret til levering af 40 mikrogram i løbet af en doseringsperiode på 10 minutter* 
				</td>
			</tr>
			<tr>
				<td>
					Maksimal doseringshastighed:
				</td>
				<td>
					6 doser per time 
				</td>
			</tr>
			<tr>
				<td>
					Blokeret periode*:
				</td>
				<td>
					<p>10 minutter (falder sammen med doseringsperioden)</p>
				</td>
			</tr>
			<tr>
				<td>
					Tilgængelige doser per enhed:
				</td>
				<td>
					80
				</td>
			</tr>
			<tr>
				<td>
					Brugsliv:
				</td>
				<td>
					24 timer eller 80 doser, afhængig af hvad der kommer først
				</td>
			</tr>
			<tr>
				<td colspan="2">
					<p class="infoSidenote">
						*(Perioden på 10 minutter er afkortet til 18 sekunder i app'en med henblik på at demonstrere brug)
					</p>
				</td>
			</tr>
		</table>
				<table class="infoPageTable infoColumn" align="left">
					<tbody>
						<th>
							<h3>FUNKTIONER</h3>
						</th>
						<tr>
							<td>
								<ul>
									<li>Knap til dosering efter behov</li>
									<li>Lysemitterende diode (LED), som angiver: 
										<ul>
											<li>Når en dosis leveres (Grøn)</li>
											<li>Når der sker en fejl (Rød)</li>
										</ul>
									</li>
								</ul>
							</td>
						</tr>
					</tbody>
				</table>
				<table class="infoPageTable infoColumn" align="left">
					<tbody>
						<tr>
							<td>
								<ul>
									<li>Flydende krystal-skærm (Liquid-crystal display, LCD), som angiver:</li>
										<ul>
											<li>Antallet af leverede doser</li>
											<li>Når en dosis indgives</li>
											<li>Når der sker en fejl </li>
										</ul>
									<li>Lydtoner, der angiver dosisaktivering og forskellige systemadvarsler</li>
									<li>Trykfølsomt klæbestof, der klæber IONSYS sikkert fast på patientens hud</li>
								</ul>
							</td>
						</tr>
					</tbody>
				</table>
				<table class="infoPageTable smpc">
					<tr>
						<td>
							<h3>
								IONSYS 40 MICROGRAMS PER DOSE TRANSDERMAL SYSTEM (FENTANYL)
							</h3>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								ABBREVIATED PRESCRIBING INFORMATION 
							</h3>
							<h4>
								(refer to full Summary of Product Characteristics [SmPC] before prescribing).
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Presentations
							</h3>
							<h4>
								IONSYS is a transdermal system. Each IONSYS system contains fentanyl hydrochloride equivalent to 9.7 mg of fentanyl and delivers 40 micrograms fentanyl per dose, to a maximum of 80 doses (3.2 mg/24 hours).

							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Indication
							</h3>
							<h4>
								IONSYS is indicated for the management of acute moderate to severe post-operative pain in adult patients.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Posology and method of administration
							</h3>
							<h4>
								Refer to full SmPC for complete information on posology and administration. IONSYS is a patient-controlled device restricted to hospital use only. Treatment should be initiated by and remain under the guidance of a physician experienced in the management of opioid therapy. Due to the well-known potential of abuse of fentanyl, physicians should evaluate patients for a history of drug abuse.
							</h4>
							<h4>
								<i>Recommended dosage:</i> Each dose delivers 40 micrograms of fentanyl over a 10 minute period. Each unit operates for 24 hours or for 80 doses, whichever comes first, and then becomes inoperative. The maximum treatment duration is 72 hours.
							</h4>
								<i>Elderly (≥65 years): </i>No specific dose adjustment is required. Elderly patients should be observed closely for adverse effects of fentanyl.
							</h4>
							<h4>
								<i>Hepatic or renal impairment:</i> Administer with caution to patients with moderate or severe hepatic or renal impairment
							</h4>
							<h4>
								<i>Paediatric population:</i> Not recommended.
							</h4>
							<h4>
								<i>Method of administration:</i> For transdermal use only. Refer to full SmPC for complete information on method of administration and instructions for use and disposal of IONSYS.  
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Contraindications
							</h3>
							<h4>
								Hypersensitivity to active substance or any excipient.
							</h4>
							<h4>
								Severe respiratory depression or cystic fibrosis.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Special warnings and precautions for use
							</h3>
							<h4>
								IONSYS should be removed before MRI procedure, cardioversion, defibrillation, X-ray, CT scan or diathermy.
							</h4>
							<h4>
								Excessive sweating may reduce delivery of fentanyl.
							</h4>
							<h4>
								<i>Respiratory depression:</i> Significant respiratory depression may occur; patients must be observed for these effects. The use of concomitant CNS-active medicinal products may increase the risk of respiratory depression.
							</h4>
							<h4>
								<i>Chronic pulmonary disease:</i> Patients with chronic obstructive pulmonary disease or patients with conditions pre-disposing them to hypoventilation, may experience more severe adverse reactions. In such patients, opioids may decrease respiratory drive and increase airway resistance.
							</h4>
							<h4>
								<i>Head injuries and increased intracranial pressure:</i> Fentanyl should not be used in patients who may be particularly susceptible to the intracranial effects of CO2 retention. Fentanyl should be used with caution in patients with brain tumours or other significant space occupying lesions of the brain.
							</h4>
							<h4>
								<i>Cardiac disease:</i> Fentanyl may produce bradycardia or hypotension and should be administered with caution to patients with bradyarrhythmias or any significant cardiovascular disease.
							</h4>
							<h4>
								<i>Paralytic ileus:</i> Should be used with caution in patients with paralytic ileus.
							</h4>
							<h4>
								<i>Abuse potential and dependence:</i> Fentanyl has a well-known abuse potential. Physicians should evaluate patients for a history of drug abuse and follow such patients closely. 
							</h4>
							<h4>
								<i>Hepatic or renal disease:</i> Patients with hepatic or renal impairment should be observed carefully for signs of fentanyl toxicity.
							</h4>
							<h4>
								<i>Elderly patients:</i> Elderly patients should be observed carefully for adverse effects of fentanyl during IONSYS administration.
							</h4>
							<h4>
								<i>Obese patients:</i> Overall adverse reaction profile for morbidly obese patients (BMI > 40) does not suggest a meaningful difference in safety compared to patients with BMI ≤ 40. Caution is advised when prescribing IONSYS in these patients as they may be at increased risk of other respiratory conditions (i.e., sleep apnoea) potentially pre-disposing them to hypoventilation or more severe adverse reactions.
							</h4>
							<h4>
								<i>Hearing impairment:</i> IONSYS should be used with caution in patients with hearing impairment who might not be able to hear the audible signals from the system. 
							</h4>
							<h4>
								<i>Thoracic/chest and upper abdominal surgeries:</i> IONSYS should be used with caution in these patients. 
							</h4>
							<h4>
								<i>Physical status:</i> Safety of IONSYS has not been established in patients with American Society of Anesthesiologists (ASA) physical status classification IV (i.e. patients with a severe systemic disease that is a constant threat to life).
							</h4>
							<h4>
								<i>Patients with genetic polymorphisms affecting CYP3A4 and CYP3A5:</i> IONSYS should be used with caution in these patients. Published literature indicates potential for increased fentanyl exposure in patients with genetic polymorphisms affecting CYP3A4 and CYP3A5; 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Interaction with other medicinal products and other forms of interaction
							</h3>
							<h4>
								<i>Other CNS depressants:</i> Concomitant use with other CNS depressants may produce additive depressant effects. Hypoventilation, hypotension and profound sedation or coma may occur. Use of other CNS depressants concomitantly with IONSYS requires special patient care and observation.
							</h4>
							<h4>
								<i>CYP3A4 inhibitors: </i>Concomitant use of potent CYP3A4 inhibitors  or moderate CYP3A4 inhibitors  with IONSYS may result in an increase in fentanyl plasma concentrations, which could increase or prolong both the therapeutic effect and adverse reactions, and may cause serious respiratory depression. Concomitant use of potent or moderate CYP3A4 inhibitors and IONSYS is not recommended unless the patient is closely monitored.
							</h4>
							<h4>
								<i>Opioid agonists/antagonists:</i> Concomitant use of partial opioid agonists/antagonists is not recommended as they may induce withdrawal symptoms in opioid dependant patients.
							</h4>
							<h4>
								<i>Serotoninergic medicinal products:</i> Co-administration of fentanyl with a serotoninergic agent may increase the risk of serotonin syndrome. IONSYS is not recommended for use in patients who have received MAOIs within 14 days because severe and unpredictable potentiation by MAOIs has been reported. 
							</h4>
							<h4>
								<i>Topical medicines: </i>Application of IONSYS on skin on which any topical medicine has been applied should be avoided.  
							</h4>
							<h4>
								Refer to full SmPC for further information on interactions. 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Fertility, pregnancy and lactation
							</h3>
							<h4>
								<i>Pregnancy:</i> No adequate data are available for use of fentanyl in pregnant women. IONSYS should not be used in pregnancy unless clearly necessary. If IONSYS is administered to the mother during this time, an antidote for the child should be readily available.  Following long-term treatment fentanyl may cause withdrawal symptoms in the newborn.
							</h4>
							<h4>
								<i>Breast-feeding:</i> Not recommended for 24 hours following removal of IONSYS. 
							</h4>
							<h4>
								<i>Fertility:</i> There are no clinical data on the effects of fentanyl on fertility. 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Effects on ability to drive and use machines
							</h3>
							<h4>
								Patients should be advised not to drive or operate machinery if they experience somnolence, dizziness, or visual disturbance.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Undesirable effects 
							</h3>
							<h4>
								The  most commonly reported adverse reactions were nausea, vomiting, and application site reactions. The most serious adverse reactions reported were hypotension and apnoea; all patients should be closely monitored for these. Refer to full SmPC for complete information on other side effects.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Overdose
							</h3>
							<h4>
								Fentanyl overdose effects manifest as an extension of its pharmacologic actions, the most serious effect being respiratory depression. For management of respiratory depression, immediate countermeasures include removing the IONSYS system and physically or verbally stimulating the patient. These actions can be followed by administration of a specific opioid antagonist such as naloxone. Respiratory depression following an overdose may outlast the duration of action of the opioid antagonist therefore repeated administration of the antagonist may be necessary. Reversal of the narcotic effect may also result in acute onset of pain and release of catecholamines. If the clinical situation warrants, a patent airway should be established and maintained, possibly with an oropharyngeal airway or endotracheal tube. Oxygen should be administered and respiration assisted or controlled. If severe or persistent hypotension occurs, hypovolaemia should be considered and the condition should be managed with appropriate parenteral fluid therapy or other interventions. 
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Legal Category
							</h3>
							<h4>
								Prescription only
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Package Quantities & Costs 
							</h3>
							<h4>
								600 GBP for one box containing 6 IONSYS units
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Marketing Authorisation Holder
							</h3>
							<h4>
								line Therapeutics Europe Ltd, 21 St. Thomas Street, Bristol BS1 6JS, United Kingdom.
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Marketing Authorisation Number
							</h3>
							<h4>
								EU/1/15/1050/001
							</h4>
						</td>
					</tr>
					<tr>
						<td>
							<h3>
								Date of last revision of the API text
							</h3>
							<h4>
								November 2015
							</h4>
							<h4>
								Any suspected adverse reactions should be reported to the local regulatory authority [contact details to be customised per country in line with Appendix V].   
							</h4>
							<h4>
								Adverse events should also be reported to The Medicines Company [add company details tel, email and/or address]
							</h4>
						</td>
					</tr>
				</table>
			</tr>
			</tbody>
	</div>
</section>
<footer class="ionsysLogoBanner logoBannerBottom">
	<div class="ionsysLogo">
	</div>
</footer>
<div class="controlBar">
	<div class="controlButtonsContainer">
		<button id="poorSkin" class="extraButtons" disabled>PSC</button>
		<button id="EOU" class="extraButtons" disabled>
			<span>80/24</span>
		</button>		
		<button id="EOL" class="extraButtons" disabled></button>
		<button id="infoToggle" class="extraButtons">
		</button>	
	</div>
</div>
<audio id="beeper" preload="auto" src="beep.mp3"></audio>
<audio id="beeper-long" preload="auto" src="beep_long.mp3">	</audio>
<audio id="button-press" preload="auto" src="buttonpress.mp3"></audio>

</body>
<script src="http://ajax.googleapis.com/ajax/libs/jquery/1.10.2/jquery.min.js"></script>
<!-- make this a conditional if they are using phonegap and the online / cached copy is not available: -->
<script>window.jQuery || document.write('<script src="jquery-1.10.2.min.js">\x3C/script>')</script>
<script src="jquery-1.11.4-ui.min.js" type="text/javascript"></script>
<script src="jquery.ui.touch-punch.min.js" type="text/javascript"></script>
<script src="jquery.tap.js" type="text/javascript"></script>
<script src="phonegap.js"></script>
<script type="text/javascript" src="script.js"></script>
</html>